HOME Top Market Reports Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018

Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018

By: marketsandmarkets.com
Publishing Date: September 2013
Report Code: BT 2123

 

  Speak to Analyst Enquiry Before Buying
Analyst Briefing  
purchase report
download pdf  request for customisation


Profiling a cancer/tumor is about gaining knowledge about a patient’s cancer/tumor profile and identifying any genomic alterations that can help a physician to guide patients through a systemic therapy with a higher likelihood of success. Cancer profiling helps physicians to rule out therapies that are unlikely to be successful (on an individual basis) thereby minimizing the trial and error process. The global cancer/tumor profiling market is estimated to grow at a CAGR of 18.5%, to reach approximately $35 billion by 2018. North America accounts for the largest share of this market, followed by Europe. The large shares of the North American and European region can be attributed to the presence of technology providers, availability of better R&D facilities, and promising funding landscape. Emerging economics such as China, India, Japan, and other regions in Asia-Pacific and the untapped markets in Europe are expected to witness significant growth in the future. The growth in these regions will be propelled by a number of factors such as growing GDP, increasing healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

In this report, the cancer/tumor profiling market is broadly segmented across two categories, namely, market by technologies and applications. The market by technology consists of next-generation sequencing, quantitative PCR, immunohistochemistry, FISH/CISH, and microarrays. Based on applications, the market is segmented into major application areas, namely, personalized medicine, diagnostics, biomarker discovery, prognosis, and research applications.

The cancer/tumor profiling market is driven by the rising number of cancer cases. Technological advancements, to identify the exact cause of the condition, are also driving the growth of this market. Additionally, the increasing demand for safer and cost-effective treatments is further driving this market. The rapid growth of the cancer/tumor profiling market is attributed to its promising applications in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. However, lack of awareness about cancer/tumor profiling options and their potential among clinicians might result in missing out on the crucial profile of the cancer condition, resulting in poor selection of treatment and disease prognosis. This factor will have a huge impact on the addressable market for cancer/tumor profiling services.

Personalized medicine applications command the largest share, mainly due to the high demand for effective cancer treatment. Apart from its potential market value in personalized medicine and diagnostics segments, it also has a strong value and expansion opportunities in applications such as, biomarker discovery, cancer prognosis, and research applications. A number of novel tools and services offered by various biotechnology companies for tumor profiling greatly serve cancer screening and diagnostics. These tools and services aid in speeding up the development in the cancer therapeutics field and help in boosting the growth of this market.

Major players are focusing on marketing their products in emerging markets such as India, Japan, Brazil, and China. Key biotechnology and pharmaceutical companies such as Caris Life Sciences (U.S.), Proteome Sciences PLC (U.K.), Life Technologies (U.S.), Boreal Genomics, Inc. (U.S.), Oxford Gene Technology Ltd. (OGT) (U.K.), and Precision Therapeutics, Inc. (U.S.), among others, are collaborating with each other as well as with academic research universities to develop effective cancer profiling products and gain a vital space in the industry. Key trends among market participants include partnerships/collaborations, in-licensing and out-licensing technologies, and integration of multiple technologies for bringing about innovative products for personalized healthcare. Another noteworthy trend in this field is the enormity of scientific and commercial attention on cancer/tumor profiling, as this treatment option has several advantages over the current non-specific cancer treatments. There has been a consistent patenting activity going on in this field which has undergone exponential growth, with cancer profiling for a broad range of cancer biomarkers being patented. This is reflected in the extensive ongoing research activities in this market.

Taking into consideration the global health burden, research universities and companies have leveraged their patents for the development of commercial products that benefit people affected with cancer. However, there are still quite a few companies that restrict access to their proprietary technologies through strong IP protection. This complicates the utilization of scientific discoveries by researchers and creates hurdles in the adoption these methods for further research and development. In addition to intense patent activity, this field has also been garnering billion-dollar funding from federal agencies, venture capitalists, and corporate R&D investments, due to the perceived high revenue potential of cancer profiling technologies and products in the next five years. However, the purchasing and reimbursement decisions of tumor/profiling products and services would be majorly influenced by the incidence of cancers, market economics, and changing trends in healthcare and legislative reforms.

Table Of Content            
            
            
1 Introduction (Slide No. - 20)
           
  1.1 Key Take-Aways          
  1.2 Logical Assumptions For This Study Based On Reliable Sources          
  1.3 Report Scope          
  1.4 Research Methodology          
  1.5 Key Data Points From Secondary & Primary Resources          
            
2 Executive Summary (Slide No. - 27)          
            
3 Tumor Profiling Technology Landscape (Slide No. - 31)
          
  3.1 Technology Overview          
  3.2 Milestones In Cancer Research          
  3.3 Tumor Profiling Segments          
      3.3.1 Genomics         
      3.3.2 Proteomics         
      3.3.3 Metabolomics         
      3.3.4 Epigenetics         
            3.3.4.1 Epigenetic Genes Disturbed In Cancer Conditions        
            3.3.4.2 Cancers And Associated Epigenetic Disruptions        
  3.4 The Biological Organization Of The “-Omes”          
  3.5 Tumor Profiling Technologies          
      3.5.1 Next-Generation Sequencing (NGS)         
      3.5.2 Fluorescence/Chromogenic In Situ Hybridization (Fish/Cish)         
      3.5.3 Immunohistochemistry (IHC)         
      3.5.4 Microarray         
      3.5.5 Quantitative Pcr (QPCR)         
  3.6 Key Tumor Profiling Technological Innovations          
  3.7 Key Tumor Profiling Products & Services In The Market          
            
4 Tumor Profiling Research Portfolio (Slide No. - 51)          
  4.1 Tumor Profiling Research Network          
            
5 Value Chain Analysis (Slide No. - 54)          
  5.1 Overview          
  5.2 Key Stakeholders          
  5.3 Gap Analysis          
  5.4 Porter’s Five Forces Analysis          
            
6 Market Landscape Analysis  (Slide No. - 63)          
  6.1 "Tumor Profiling Technologies: Market Segmentation"          
  6.2 "Tumor Profiling Technologies: Global Impact          
  6.3 Market Forecast: Overview, 2013-2018          
  6.4 "Global Cancer Profiling: Market Revenue Forecast, 2013 – 2018"          
      6.4.1 "Global Cancer Profiling: Market Revenue, By Geography"         
      6.4.2 Global Cancer Profiling Market Share, By Geography         
      6.4.3 Global Cancer Profiling: Market Revenue, By Segment         
            6.4.3.1 Global Cancer Profiling: Market Share, By Segment        
            6.4.3.2 Genomics Market, By Region        
            6.4.3.3 Proteomics Market, By Region        
            6.4.3.4 Metabolomics Market, By Region        
            6.4.3.5 Epigenetics Market, By Region        
      6.4.4 Global Cancer Profiling Market Revenue, By Technology         
            6.4.4.1 Global Cancer Profiling Market Share, By Technology        
            6.4.4.2 Next-Generation Sequencing Market, By Region        
            6.4.4.3 Fluorescence/Chromogenic In Situ Hybridization Market, By Region        
            6.4.4.4 Immunohistochemistry Market, By Region        
            6.4.4.5 Quantitative Pcr Market, By Region        
            6.4.4.6 Microarray Market, By Region        
      6.4.5 Global Cancer Profiling Market Revenue, By Application         
            6.4.5.1 Global Cancer Profiling Market Share, By Application        
            6.4.5.2 Personalized Medicine Market, By Region        
            6.4.5.3 Biomarker Discovery Market, By Region        
            6.4.5.4 Diagnostics Market, By Region        
            6.4.5.5 Prognosis Market, By Region        
            6.4.5.6 Research Applications Market, By Region        
  6.5 Market Dynamics          
      6.5.1 Drivers         
            6.5.1.1 Tumor Profiling – Impact Analysis Of Drivers        
      6.5.2 Restraints         
            6.5.2.1 Tumor Profiling – Impact Analysis Of Restraints        
            
7 Technology Adoption And Development Potential, By Geography   (Slide No. - 114)
  7.1 Geographic Adoption And Development Potential – Overview          
  7.2 North America          
  7.3 Europe          
  7.4 Asia          
  7.5 Rest Of The World (ROW)          
            
8 Technology Investment Analysis  (Slide No. - 122)         
  8.1 Investment Climate Assessment          
  8.2 Investor Network          
  8.3 Funds And Investments On Tumor/Cancer Profiling          
  8.4 Funds And Investments From Nih – By Fiscal Year          
  8.5 Funds And Investments From Nih – By Its Associated Institutes/Centers (2008 - 2013)          
  8.6 Top 10 Organizations To Receive Highest Funding From Nih During 2008-2013          
  8.7 Funds From The American Cancer Society As Of September 01, 2013 For Various Cancer Types          
  8.8 Insights On Current And Future Technology Investment Trends          
             
9 Competitive Landscape Analysis (Slide No. - 136)          
  9.1 Competitive Landscape Analysis          
  9.2 Key Acquisitions/Partnerships/Agreements/Collaborations (2010-2013)          
  9.3 Technologies Available For Licensing & Acquisition For Stakeholders          
             
10 Patent Analysis  (Slide No. - 141)         
   10.1 Overview          
   10.2 Ip Strength Analysis – By Cancer Segments           
            
11 Analyst Insights And Recommendations (Slide No. - 144)          
   11.1 Key Insights On The Market          
   11.2 Strategic Recommendations          
   11.3 Open Opportunity Invitations In The Field For Business Development          
            
12 Company Profiles  (Slide No. - 148)          
   12.1 Boreal Genomics, Inc.          
   12.2 Caris Life Sciences          
   12.3 Genomic Health, Inc.          
   12.4 Illumina, Inc.          
   12.5 Life Technologies Corporation          
   12.6 Neogenomics Laboratories          
   12.7 Oxford Gene Technology Ltd          
   12.8 Precision Therapeutics, Inc.          
   12.9 Biotheranostics          
   12.10 Proteome Sciences Plc          
   12.11 Agendia Nv          
   12.12 Nanostring Technologies          
   12.13 Rational Therapeutics          
   12.14 Oncopath Laboratory          
   12.15 Ribomed Biotechnologies          
      
            
List Of Tables (22 Tables)         
           
Tab - 1 Global Tumor Profiling Market, 2013 – 2018 ($Billion)           
Tab - 2 Market Revenue, By Geography, 2013 – 2018 ($Billion) 
Tab - 3 Global Market, By Segment, 2013 – 2018 ($Billion) 
Tab - 4 Genomics Market, By Region, 2013 – 2018 ($Billion)           
Tab - 5 Proteomics Market, By Region, 2013 – 2018 ($Billion)           
Tab - 6 Metabolomics Market, By Region, 2013 – 2018 ($Billion)           
Tab - 7 Epigenetics Market, By Region, 2013 – 2018 ($Billion)           
Tab - 8 Global Cancer Profiling Market, By Technology, 2013 – 2018 ($Billion)  
Tab - 9 Next Generation Sequencing Market, By Region, 2013 – 2018 ($Billion)          
Tab - 10 Fluorescence/Chromogenic In Situ Hybridization Market, By Region, 2013 – 2018 ($Billion)
Tab - 11 Immunohistochemistrymarket, By Region, 2013 – 2018 ($Billion)           
Tab - 12 Quantitative PCR, By Region, 2013 – 2018 ($Billion)           
Tab - 13 Microarray Market, By Region, 2013 – 2018 ($Billion)           
Tab - 14 Global Tumor Profiling Market, By Application, 2013 – 2018 ($Billion)        
Tab - 15 Personalized Medicine Market, By Region, 2013 – 2018 ($Billion)     
Tab - 16 Biomarker Discovery Market, By Region, 2013 – 2018 ($Billion)           
Tab - 17 Diagnostics Market, By Region, 2013 – 2018 ($Billion)           
Tab - 18 Prognosis Market, By Region, 2013 – 2018 ($Billion)           
Tab - 19 Research Applications Market, By Region, 2013 – 2018 ($Billion)       
Tab - 20 Funds By Nih & Its Associated Centers, 2008-2013 ($Million)           
Tab - 21 Projects And Funds By Nih & Its Associated Centers, 2008-2013 ($Million) 
Tab - 22 Projects And Funds From The American Cancer Society As Of Sep 01, 2013 ($Million)
   
                         
List Of Figures (50 Figures)            
            
Fig - 1 Global Tumor Profiling Market, 2013 – 2018 ($Billion)           
Fig - 2 Porter’s Value Chain Analysis For The Cancer Profiling Market          
Fig - 3 Global Cancer Profiling Market, 2013 – 2018 ($Billion)           
Fig - 4 Market Revenue, By Geography, 2013 – 2018 ($Billion)          
Fig - 5 Global Market, By Geography, 2012 – 2018            
Fig - 6 Global Market By Segment, 2013 – 2018 ($Billion)   
Fig - 7 Global Market: Growth Rate, By Segment, 2013 – 2018       
Fig - 8 Global Market, By Segment, 2013 – 2018            
Fig - 9 Genomics Market, By Region, 2013 – 2018 ($Billion)           
Fig - 10 Genomics Market, By Region, 2013 – 2018            
Fig - 11 Proteomics Market, By Region, 2013 – 2018 ($Billion)           
Fig - 12 Proteomics Market,  By Region, 2013 – 2018            
Fig - 13 Metabolomics Market, By Region, 2013 – 2018 ($Billion)           
Fig - 14 Metabolomics Market, By Region, 2013 - 2018           
Fig - 15 Epigenetics Market, By Region, 2013 – 2018 ($Billion)           
Fig - 16 Epigenetics Market, By Region, 2013 – 2018            
Fig - 17 Global Cancer Profiling Market, By Technology, 2012 – 2018 ($Billion)          
Fig - 18 Global Cancer Profiling Market, By Technology, 2012 – 2018           
Fig - 19 Global Cancer Profiling Market, By Technology, 2013 – 2018            
Fig - 20 Next Generation Sequencing Market, By Region, 2013 – 2018 ($Billion)  
Fig - 21 Next-Generation Sequencing Market, By Region, 2013 – 2018            
Fig - 22 Fluorescence/Chromogenic In Situ Hybridization Market, By Region, 2013 – 2018 ($Billion)    
Fig - 23 Fluorescence/Chromogenic In Situ Hybridization Market, By Region, 2013 – 2018 
Fig - 24 Immunohistochemistrymarket, By Region, 2013 – 2018 ($Billion)           
Fig - 25 Immunohistochemistry Market, By Region, 2013 – 2018           
Fig - 26 Quantitative Pcr, By Region, 2013 – 2018 ($Billion)           
Fig - 27 Quantitative Pcr Market, By Region, 2013 – 2018           
Fig - 28 Microarray Market, By Region, 2013 – 2018 ($Billion)           
Fig - 29 Microarray Market, By Region, 2013 – 2018            
Fig - 30 Global Cancer Profiling Market, By Application, 2012 – 2018 ($Billion)        
Fig - 31 Global Cancer Profiling Market Share , By Application, 2012 – 2018      
Fig - 32 Global Cancer Profiling Market, By Application, 2013 – 2018             
Fig - 33 Personalized Medicine Market, By Region, 2013 – 2018 ($Billion)        
Fig - 34 Personalized Medicine Market, By Region, 2013 – 2018            
Fig - 35 Biomarker Discovery Market, By Region, 2013 – 2018 ($Billion)           
Fig - 36 Biomarker Discovery Market, By Region, 2013 – 2018            
Fig - 37 Diagnostics Market, By Region, 2013 – 2018 ($Billion)           
Fig - 38 Diagnostics Market, By Region, 2013 – 2018            
Fig - 39 Prognosis Market, By Region, 2013 – 2018 ($Billion)           
Fig - 40 Prognosis Market, By Region, 2013 – 2018            
Fig - 41 Research Applications Market, By Region, 2013 – 2018 ($Billion)   
Fig - 42 Research Applicatons Market, By Region, 2013 – 2018            
Fig - 43 Tumor Profiling – Market Dynamics           
Fig - 44 Tumor Profiling Market Cagr, By Geography, 2013 – 2018   
Fig - 45 Metabolomics Market, By Region, 2013 – 2018 ($Billion)           
Fig - 46 Funding By Nih & Its Associated Centers, 2008-2013 ($Million)           
Fig - 47 Funding By Nih & Its Associated Centers, 2008-2013 ($Million)           
Fig - 48 Funding By American Cancer Society ($Million)           
Fig - 49 Total No. Of Patents Filed, By Cancer Segments           
Fig - 50 Cancer Segments Ip Share In 2013

The global market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment.

The market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry.

North America is a significant contributor to the market, followed by Europe, due to the presence of technology providers and better R&D facilities. The new markets that are expected to grow at a brisk pace are emerging economics such as China, India, Japan, and other regions of Asia-Pacific and the untapped markets of Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

Key players in market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina, Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed Biotechnologies Inc. (U.S.).

Cancer/Tumor Profiling Market

Source: Expert Interviews, Annual Reports, Secondary Research Data, and MarketsandMarkets Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports